Caplin Point Laboratories
- Market Cap
- ₹15,424 Cr
- P/E
- 22.39
Key Fundamentals
SmallcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 24.20%
- Debt to Equity
- 0.00
- EPS (TTM)
- ₹90.64
- Book Value
- ₹513.34
- Market Cap
- ₹15,424 Cr
- P/E (TTM)
- 22.39
- P/B
- 3.95
- ROE
- 20.90%
- Dividend Yield
- 0.38%
- EBITDA
- ₹876 Cr
- 52W High
- ₹2,990.00
- 52W Low
- ₹1,500.30
- Day Range
- ₹2,020.00 – ₹2,126.00
- Volume
- 1,65,087
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| 2,029.10 | 22.39 | 15,424 | 3.95 | 0.38% | 20.90% | 24.20% | 2,383 | 700 | |
| Median 8 companies | 1,957.00 | 41.35 | 1,21,840 | 4.69 | 0.48% | 17.40% | 19.15% | 22,770 | 2,808 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 65
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 72
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 51
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 81
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 30
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 43
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
4- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 21.4% CAGR over last 5 years
- Company's median sales growth is 19.9% of last 10 years
No weaknesses listed
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 2 | 5 |
| Oscillators | Strong Bullish | 2 | 2 | 5 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Strong Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 26.74
- Bullish
- MACD (12,26,9)
- −83.89
- Bearish
- SMA (50)
- 2,480.50
- Bearish
- SMA (200)
- 2,203.61
- Bearish
As of
Analyst Rating
2 of 2 analysts rate Buy, 0 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | Irregular period |
|---|---|
| 5Y | +15.57% |
| 3Y | +14.24% |
| 1Y | +12.91% |
| TTM | +16.87% |
Net profit
| 10Y | Irregular period |
|---|---|
| 5Y | +20.96% |
| 3Y | +19.91% |
| 1Y | +20.15% |
| TTM | +17.45% |
Operating cash flow
| 10Y | Irregular period |
|---|---|
| 5Y | +14.22% |
| 3Y | +24.50% |
| 1Y | +21.06% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | Irregular period |
|---|---|
| 5Y | +3.97 pp |
| 3Y | +4.85 pp |
| 1Y | +1.37 pp |
| TTM | +0.65 pp |
Revenue by year
| Mar 2017 | ₹402 Cr |
|---|---|
| Mar 2018 | ₹540 Cr |
| Mar 2019 | ₹649 Cr |
| Mar 2020 | ₹863 Cr |
| Mar 2021 | ₹1,061 Cr |
| Mar 2022 | ₹1,269 Cr |
| Mar 2023 | ₹1,467 Cr |
| Mar 2024 | ₹1,694 Cr |
| Mar 2025 | ₹1,937 Cr |
| Mar 2026 | ₹2,187 Cr |
Net profit by year
| Mar 2017 | ₹96.00 Cr |
|---|---|
| Mar 2018 | ₹145 Cr |
| Mar 2019 | ₹177 Cr |
| Mar 2020 | ₹215 Cr |
| Mar 2021 | ₹251 Cr |
| Mar 2022 | ₹308 Cr |
| Mar 2023 | ₹377 Cr |
| Mar 2024 | ₹461 Cr |
| Mar 2025 | ₹541 Cr |
| Mar 2026 | ₹650 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Caplin Point Laboratories trades at a PE of 23x with an EPS of ₹90.64 as of 2026-11-19, backed by a 10-year compounded profit growth of 30% and a near debt-free balance sheet (debt-to-equity of 0.07). The stock sits about 30% below its 52-week high of ₹2,990, with a market cap of ₹15,845 Cr and ROE of 17.89%.
- Virtually debt-free with a debt-to-equity ratio of just 0.07, giving the company significant financial flexibility and resilience through business cycles.
- Exceptional long-term profit compounding at 30% CAGR over 10 years, indicating a durable and scalable business model.
- Compounded sales growth of 25% over 10 years and a median sales growth of 19.9% over the last decade point to consistent top-line expansion.
- ROCE of 21.96% reflects efficient capital deployment, well above the cost of capital for most Indian pharmaceutical companies.
- 10-year average ROE of 25% demonstrates sustained ability to generate strong returns on shareholders' equity over a long period.
- 5-year compounded profit growth of 21% outpaces the 5-year sales CAGR of 16%, suggesting improving margins or operating leverage.
- TTM sales growth of 17% is an acceleration from the 3-year CAGR of 14%, suggesting recent momentum in revenue generation.
- Dividend yield of only 0.38% offers minimal income return to shareholders, indicating limited near-term cash distribution.
- Price-to-book of 4.06x is elevated, meaning the market is pricing in significant future growth that must be delivered to justify the premium.
- TTM profit growth of 17% has decelerated meaningfully from the 10-year CAGR of 30% and 5-year CAGR of 21%, signalling a potential growth slowdown.
- Last year ROE of 21% and current ROE of 17.89% show a declining trend from the 10-year average of 25%, indicating diminishing return efficiency.
- The stock has fallen about 30% from its 52-week high of ₹2,990 to ₹2,084.6, reflecting recent negative sentiment or earnings concern among market participants.
- With a market cap of ₹15,845 Cr, the company is a mid-cap that can be subject to higher volatility and lower liquidity compared to large-cap pharma peers.
- The 1-year stock CAGR of 8% significantly trails the 5-year CAGR of 20%, indicating near-term underperformance relative to its own historical trend.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Caplin Point Labs is laying out an ambitious growth roadmap centered on doubling its US business in FY27 and expanding PAT margins toward 25-26%. The COL-II facility expected by August 2027 adds a visible medium-term revenue driver. No material headwinds surfaced in this update cycle. The trend is constructive, with execution on US growth and facility timelines being the key variables to watch.
- US business to double FY27 Nov 19
CSU (US business) revenue and profit are anticipated to double in FY27, with the company targeting 20-25% growth in the U.S. market.
- COL-II facility by Aug 2027 Nov 19
COL-II facility completion is expected by August 2027, positioned to drive incremental revenue in FY28-29.
- PAT margin expansion target Nov 19
Company targets 20-21% PAT margins currently with a goal of reaching 25-26% over time.
- FY27 growth guidance outlined Nov 19
Caplin Point Labs laid out its FY27 roadmap including US growth targets of 20-25%, margin goals, and facility timelines without any immediate catalysts.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 | 630 |
| Expenses | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 | 397 | 407 |
| Operating Profit | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 | 213 | 223 |
| OPM % | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% | 35% | 35% |
| Other Income | 20.43 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 | 34 | 33.29 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.22 |
| Depreciation | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 | 22 | 23.49 |
| PBT | 146 | 145 | 146 | 154 | 169 | 177 | 177 | 184 | 201 | 204 | 213 | 225 | 233 |
| Tax % | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% | 20% | 22% |
| Net Profit | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 | 182 |
| EPS (₹) | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.10 | 20.32 | 21.56 | 22.38 | 23.27 | 23.43 |
| YoY Sales growth | 14 | 17 | 16 | 16 | 18 | 13 | 11 | 11 | 11 | 10 | 19 | 20 | 18 |
Profit & Loss
₹ Cr| Particulars | Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 2,187 | 2,383 |
| Expenses | 192 | 175 | 276 | 345 | 417 | 603 | 732 | 874 | 1,025 | 1,142 | 1,287 | 1,422 | 1,553 |
| Operating Profit | 60 | 64 | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 651 | 765 | 831 |
| OPM % | 24% | 27% | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% | 34% | 35% | 35% |
| Other Income | 3 | 4 | 10 | 13 | 19 | 41 | 23.54 | 38.75 | 55.98 | 66.94 | 92 | 111 | 129 |
| Interest | 1 | 0 | 1 | 0.06 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 53 | 66 | 73 | 83 |
| PBT | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 | 677 | 803 | 875 |
| Tax % | 23% | 24% | 21% | 23% | 22% | 20% | 20% | 20% | 16% | 18% | 20% | 19% | — |
| Net Profit | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 650 | 700 |
| EPS (₹) | 5.43 | 6.05 | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 84.36 | 90.64 |
| Div. Payout % | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% | 8% | 8% | 9% | — |
| Sales growth | 45 | 38 | 68 | 34 | 20 | 33 | 23 | 20 | 16 | 16 | 14 | 13 | 17 |
Balance Sheet
₹ Cr| Particulars | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 78 | 113 | 210 | 349 | 582 | 858 | 954 | 1,252 | 1,649 | 2,084 | 2,619 | 3,355 | 3,887 |
| Borrowings | 2 | 2 | 1 | 1 | 36 | 113 | 235 | 219 | 222 | 219 | 222 | 221 | 5 |
| Other Liabilities | 134 | 137 | 133 | 136 | 109 | 139 | 159 | 250 | 305 | 380 | 352 | 446 | 468 |
| Total Liabilities | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,038 | 4,375 |
| Fixed Assets | 113 | 144 | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 453 | 546 | 580 | 710 |
| CWIP | 31 | 0 | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 | 144 | 234 | 215 |
| Investments | 0 | 0 | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 | 590 | 859 | 966 |
| Other Assets | 85 | 122 | 186 | 269 | 436 | 772 | 1,033 | 1,343 | 1,410 | 1,753 | 1,928 | 2,365 | 2,484 |
| Total Assets | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,038 | 4,375 |
Cash Flow
₹ Cr| Particulars | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 50 | 42 | 68 | 66 | 83 | 45 | 269 | 337 | 271 | 318 | 432 | 523 |
| Investing | −23 | −6 | −36 | −69 | −100 | −54 | −30 | −377 | −216 | −319 | −333 | −582 |
| Financing | −9 | −14 | −7 | −12 | 90 | 80 | −24 | −41 | −28 | −38 | −38 | −46 |
| Net Cash Flow | 19 | 23 | 25 | −14 | 73 | 70 | 215 | −81 | 27 | −39 | 61 | −105 |
| Free Cash Flow | 24 | 34 | 43 | 18 | 18 | −32 | 195 | 246 | 78 | 173 | 241 | 275 |
| CFO/EBITDA | 103 | 92 | 73 | 53 | 54 | 38 | 102 | 106 | 81 | 77 | 86 | 87 |
Ratios
| Particulars | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 8 | 12 | 30 | 85 | 90 | 97 | 96 | 91 | 98 | 117 | 119 | 138 |
| Inventory Days | 37 | 57 | 44 | 44 | 47 | 210 | 139 | 149 | 159 | 183 | 159 | 181 |
| Days Payable | 112 | 168 | 155 | 144 | 76 | 57 | 68 | 102 | 84 | 116 | 103 | 125 |
| Cash Conversion Cycle | −67 | −99 | −81 | −16 | 61 | 251 | 166 | 138 | 173 | 184 | 175 | 194 |
| Working Capital Days | −128 | −114 | −29 | 47 | 104 | 167 | 145 | 165 | 144 | 166 | 174 | 199 |
| ROCE % | 68% | 62% | 68% | 63% | 45% | 33% | 28% | 28% | 26% | 26% | 26% | 24% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Caplin Point Laboratories insights
72 extracted metrics across FY12–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- 12 Nov 2026
- 12 Aug 2026
- 19 Nov 2026
- General announcements 17 Nov 2026
Frequently Asked Questions about Caplin Point Laboratories
What does Caplin Point Laboratories Ltd do?
Where is Caplin Point Laboratories Ltd (CAPLIPOINT) listed?
Which sector does Caplin Point Laboratories Ltd belong to?
What is the market capitalisation of Caplin Point Laboratories Ltd?
What is the PE ratio of Caplin Point Laboratories Ltd?
What is the 52-week high and low of Caplin Point Laboratories Ltd?
Does Caplin Point Laboratories Ltd pay dividends?
What is the Return on Equity (ROE) of Caplin Point Laboratories Ltd?
Company Information
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CAPLIPOINT.md for Caplin Point Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.